Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-04-01
2010-11-23
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S495000
Reexamination Certificate
active
07838548
ABSTRACT:
The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.
REFERENCES:
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6835721 (2004-12-01), Hawkins et al.
patent: 7202234 (2007-04-01), Chow et al.
patent: 1 147 117 (2004-06-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 00/44758 (2000-08-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO 03/020760 (2003-03-01), None
patent: WO 03/099195 (2003-12-01), None
Aliprantis et al., “Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-Like Receptor-2,”Science285(5428): 736-9, 1999.
Asai et al., “Bacterial Fimbriae and Their Peptides Activate Human Gingival Epithelial Cells Through Toll-Like Receptor 2,”Infect Immun. 69(12): 7387-95, 2001.
Asea et al., “Novel Signal Transduction Pathway Utilized by Extracellular HSP70: Role of Toll-Like Receptor (TLR) 2 and TLR4,”J Biol Chem. 277(17):15028-34, 2002.
Baker et al., “Normal Keratinocytes express Toll-Like Receptors (TLRs) 1, 2 and 5: Modulation of TLR Expression in Chronic Plaque Psoriasis,”Br J Dermatol. 148(4): 670-9, 2003.
Brightbill et al., “Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors,” 285(5428): 732-6, 1999.
Bsibsi et al., “Broad Expression of Toll-Like Receptors in the Human Central Nervous System,”J Neuropathol Exp Neurol. 61(11): 1013-21. 2002.
Decker, “Sepsis: Avoiding Its Deadly Toll,”J Clin Invest. 113(10):1473-81. 2004.
Edfeldt et al., “Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation,”Circulation. 105(10): 1158-61, 2002.
Flo et al. “Human Toll-Like Receptor 2 Mediates Monocyte Activation byListeriamonocytogenes, but Not by Group B Streptococci or Lipopolysaccharide,”J Immunol. 164(4):2064-9, 2000.
Fusunyan et al., “Evidence for an Innate Immune Response in the Immature Human Intestine: Toll-Like Receptors on Fetal Enterocytes,”Pediatr Res. 49(4): 589-93, 2001.
Hoffman et al., “TLR-Targeted Therapeutics,”Nature Reviews Drug Discovery. 2005, 4, 879-880.
Ingalls et al., “Differential Roles of the TLR2 and TLR4 in the Host Response to Gram-Negative Bacteria: Lessons from a Lipopolysaccharide-Deficient Mutant of Neisseria Meningitidis,”J Endotoxin Res. 6(5):411-5, 2000.
International Search Report and Written Opinion from International Application No. PCT/US04/35447 dated Feb. 7, 2005 and mailed Jun. 7, 2005.
Kang et al., “Detection of Toll-Like Receptor 2 (TLR2) Mutation in the Lepromatous Leprosy Patients,”FEMS Immunol Med Microbiol. 31(1): 53-8, 2001.
Kim et al., “Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses,”J Immunol. 169(3): 1535-41, 2002.
Lien et al., “Toll-Like Receptor 2 Functions as a Pattern Recognition Receptor for Diverse Bacterial Products,”J Biol Chem. 274(47): 33419-25, 1999.
Marshall et al., “Toll-Like Receptor-Mediated Activation of Mast Cells: Implications for Allergic Disease?,”Int Arch Allergy Immunol. 132(2):87-97, 2003.
Marshak-Rothstein, “Toll-Like Receptors in Systemic Autoimmune Disease,”Nat Rev lmmunol. 6(11): 823-35, 2006.
McInturff et al., “The Role of Toll-Like Receptors in the Pathogenesis and Treatment of Dermatological Disease,”J Invest Dermatol. 125(1):1-8, 2005.
McNamara et al., “Signaling Networks Controlling Mucin Production in Response to Gram-Positive and Gram-Negative Bacteria,”Glycoconi J. 8(9):715-22, 2001.
Mel'nik et al., “Complex Lipids,” Zhurnal Obshchei Khimi 37:2452-2455, 1967.
Meng et al., “Antagonistic Antibody Prevents Toll-Like Receptor 2-Driven Lethal Shock-Like Syndromes,”J Clin Invest. 113(10):1387-9, 2004.
Murray et al., “Lipopolysaccharide from the Periodontal PathogenPorphyromonas gingivalisPrevents Apoptosis of HL60-Derived Neutrophils In Vitro,”Infect Immun. 71(12): 7232-5, 2003.
Pålsson-McDermott et al., “The Potential of Targeting Toll-Like Receptor 2 in Autoimmune and Inflammatory Diseases,”Ir J Med Sci. 176(4): 253-60, 2007.
Rock et al., “A Family of Human Receptors Structurally Related to Drosophila Toll,”Proc Natl Acad Sci USA. 95(2): 588-93, 1998.
Schwandner et al., “Peptidoglycan- and Lipoteichoic Acid-Induced Cell Activation is Mediated by Toll-Like Receptor 2,”J Biol Chem. 274 (25): 17406-9, 1999.
Seya et al., “A Lipoprotein Family fromMycoplasma fermentansConfers Host Immune Activation Through Toll-Like Receptor 2,”Int J Biochem Cell Biol. 34(8): 901-6, 2002.
Sobek et al., “Direct Toll-Like Receptor 2 Mediated Co-Stilmulation of T Cells in the Mouse System as a Basis for Chronic Inflammatory Joint Disease,”Arthritis Res Ther. 6(5):R433-46, 2004.
Spyvee et al., “Toll-Like Receptor 2 Antagonists. Part 1: Preliminary SAR Investigation of Novel Synthetic Phospholipids,”Bioorg Med Chem Lett. 15(24):5494-8. 2005.
Supplementary Partial European Search Report from EP 04 79 6426, dated Nov. 21, 2008 (search completed Nov. 17, 2008).
Takeuchi et al., “Differential Roles of TLR2 and TLR4 in Recognition of Gram-Negative and Gram-Positive Bacterial Cell Wall Components,”Immunity11(4): 443-51, 1999.
Underhill et al., “The Toll-Like Receptor 2 is Recruited to Macrophage Phagosomes and Discriminates Between Pathogens,”Nature401(6755):811-5, 1999.
Wedzicha, “Exacerbations: Etiology and Pathophysiologic Mechanisms,”Chest. 121(5 Suppl):136S-141S, 2002.
Wetzler, “The Role of Toll-Like Receptor 2 in Microbial Disease and Immunity,”Vaccine. 1;21 Suppl 2:S55-60, 2003.
Yang et al., “Toll-like Receptor-2 Mediates Lipopolysaccharide-Induced Cellular Signaling,” Nature 395(6699):284-288, 1998.
Yoshimura et al., “Cutting Edge : Recognition of Gram-Positive Bacterial Cell Wall Components by the Innate Immune System Occurs via Toll-Like Receptor 2,”Immunol. 163(1): 1-5, 1999.
Zuany-Amorim et al., “Toll-Like Receptors as Potential Therapeutic Targets for Multiple Diseases,”Nat Rev Drug Discov. 1(10):797-807, 2002.
Extended European Search Report from European Patent Application No. 04796426.7, dated Mar. 4, 2010.
Chow Jesse
Gusovksy Fabian
Hawkins Lynn
Spyvee Mark
Anderson Rebecca L
Clark & Elbing LLP
Eisai R&D Management Co., Ltd.
Nolan Jason M
LandOfFree
Compounds and methods for treating toll-like receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treating toll-like receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treating toll-like receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183585